Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and
potentially permanent side effect of cancer treatment. For the management of OIPN, accurate …

(1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are
available on the long-term prevalence and consequences of chemotherapy-induced …

The increasing availability of sophisticated methods to characterize human genetic variation
has enabled pharmacogenetic data to be used not only to predict responses to treatment (in …

Peripheral neurotoxicity is one of the most distressing side effects of oxaliplatin therapy for
cancer. Indeed, most patients that received oxaliplatin experience acute and/or chronic …

Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating
complication of multiple chemotherapeutic agents that can affect patients of all ages, across …

Chemotherapy-induced peripheral neuropathy is one of the most frequent dose-limiting side
effects, observed in patients receiving antineoplastic agents, persisting for up to two years …

Simple Summary Voltage-gated sodium channels are membrane proteins that change
conformation in response to depolarization of the membrane potential, allowing sodium ions …

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal
cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological …